Clinical Trial

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

Study acronym: RAiSiN
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate triple therapy with nsMRA, RASi and SGLT2i on albuminuria in individuals with T2D and CKD
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-06.
Trial Details
NCT Number NCT06727409
Lead Sponsor Chinese University of Hong Kong
Conditions Patients With Type 2 Diabetes
Enrollment 82 participants
Start Date 2024-12-12
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-05